drugset / Trial / NCT06486337
CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single arm, multicenter study to evaluate the safety and efficacy of CMOP±R in patients with newly diagnosed non-Hodgkin's lymphoma.
Timeline
- Start
- 2024-07-10
- Primary completion
- 2025-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 15 mg | — |
| Subject | Mitoxantrone | Small molecule | 18 mg/m2 | — |
| Subject | Prednisone | Other / unclassified | 100 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Vinblastine | Small molecule | — | — |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | — |
| Subject | Vindesine | Small molecule | 2 mg/m2 | — |
| Subject | Vindesine | Small molecule | 3 mg/m2 | — |